Evonik broke ground on a biotechnology expansion at its Fermas site in Slovakia as part of an approximately EUR 80 million investment. The company said the project will add downstream fermentation technology to increase capacity for development and manufacture of complex pharmaceutical intermediates. Evonik expects completion in early 2028 and projected roughly 50 new jobs, positioning the Fermas hub to serve drug substance customers with more scalable bioprocessing capabilities. The expansion underscores how midstream and downstream capacity building continues to be a strategic focus for sponsors seeking contract manufacturing scale and consistency in regulated workflows.